IMMUNOISOLATION BIOCAPSULES FOR PANCREATIC ISLET CELLS

用于胰岛细胞的免疫隔离生物胶囊

• 批准号: 6668716
• 负责人: FRANCIS JOSEPH MARTIN
• 金额: $ 39.21万
• 依托单位: IMEDD, INC.
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-20 至 2004-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6668716
• 关键词: artificial endocrine pancreas; cell sorting; cell transplantation; dogs; extracellular matrix; gene delivery system; implant; insulin; laboratory rat; pancreas transplantation; pancreatic islets; secretion; swine; technology /technique development; tissue /cell culture; tissue /cell preparation

DESCRIPTION (provided by applicant): The objective of this Phase II research grant application is to develop a biocapsule implant containing insulin producing islet cells and then test the implant in vitro and in vivo models to set the stage for clinical development of the product with a pharmaceutical partner. Results from the Phase I program demonstrated that nanopore membranes can effectively immunologically protect xenograft insulin producing cells suspended in a matrix by allowing passage of glucose, nutrients and insulin while restricting entry of immunoglobulins and other components that may attack and destroy insulin producing cells. The Phase II program will develop a prototype implant suitable for preclinical testing in small and large animal models, if successful, this implant promises to replace insulin injections with an implant containing islet cells that produce insulin in response to the patients demands, maintaining normal levels of blood glucose. Unlike other islet cell transplantation, this approach can make use of a potentially large supply of islet cells from pigs or human stem cells without the need for any immunosuppressive therapy. The implant will keep transplanted islet cells sequestered from the recipient's immune system. It will be durable, rechargeable and, if problems develop, removable.

描述（由申请人提供）：本II期研究资助申请的目的是开发一种含有产生胰岛素的胰岛细胞的生物胶囊植入物，然后在体外和体内模型中测试植入物，为与制药合作伙伴一起进行产品的临床开发奠定基础。I期项目的结果表明，纳米孔膜可以有效地免疫保护悬浮在基质中的异种移植胰岛素产生细胞，允许葡萄糖、营养物质和胰岛素通过，同时限制免疫球蛋白和其他可能攻击和破坏胰岛素产生细胞的成分的进入。二期项目将开发一种原型植入物，适用于小型和大型动物模型的临床前测试，如果成功，这种植入物有望用含有胰岛细胞的植入物取代胰岛素注射，胰岛细胞可以根据患者的需求产生胰岛素，维持正常的血糖水平。与其他胰岛细胞移植不同，这种方法可以利用来自猪或人类干细胞的潜在大量胰岛细胞供应，而不需要任何免疫抑制治疗。这种植入物将使移植的胰岛细胞与受体的免疫系统隔离。它将是耐用的，可充电的，如果出现问题，可拆卸。